Highlights of ASH ® is Coming to China and Uruguay

The immunomodulatory drug lenalidomide can induce striking hematologic and cytogenetic responses in patients with myelodysplastic syndromes (MDS), especially among patients whose clonal cells bear a somatic deletion of the long arm of chromosome 5q (del(5q)). Unfortunately, most patients whose cytopenias and burden of clonal cells improve during lenalidomide therapy will relapse within three years — including the approximately 45 percent of patients with lower-risk del(5q) MDS who achieve a complete cytogenetic remission.